News & Events

• March 17, 2020
  

  C-Path to Lead Multi-Stakeholder Engagement on FDA’s Proposed Novel Framework to Enhance the Pediatric Medical Device Ecosystem

  C-Path today announced it has been awarded a grant to conduct stakeholder engagement to garner insights, feedback and refinement of the FDA Center for Devices and Radiological Health’s proposed framework to enhance the pediatric medical device ecosystem and to develop a strategic plan for implementation.

• March 12, 2020
  

  C-Path Appoints Dr. Klaus Romero as Chief Science Officer

  The Critical Path Institute (C-Path) today announced the appointment of Klaus Romero, M.D., M.S., F.C.P., as its new Chief Science Officer (CSO) effective April 1, 2020. Dr. Romero, a clinical pharmacologist and epidemiologist with more than 17 years combined experience in academic and pharmaceutical clinical research, translational sciences, pharmacometrics, modeling and simulation and pharmacoepidemiology, has been with C-Path since December 2007. His most recent role has been as Executive Director of Clinical Pharmacology and Quantitative Medicine. He will continue in dual roles as CSO and head of the Quantitative Medicine Program.

• January 29, 2020
  

  ERA4TB, an International Consortium to Accelerate the Development of Comprehensive Treatments Against Tuberculosis

  C-Path, Ltd. and more than 30 partners from 13 countries participate in the ERA4TB project.

  The ERA4TB (European Regimen Accelerator for Tuberculosis) project is a public-private initiative dedicated to the development of drugs against tuberculosis. With a team of more than thirty organizations and a budget of over 200 million euros ERA4TB will focus on developing a new, improved tuberculosis treatment. The partners will share their expertise, knowledge and resources to rapidly progress new candidate drugs into clinical trials.

• October 15, 2019
  

  C-Path, CDISC Develop Standard to Represent Data for Animal Rule Studies

  C-Path and CDISC are pleased to announce the release of a global Foundational Standard that describes how to represent data for the natural history and efficacy studies conducted in animals submitted to applications under the U.S. Food and Drug Administration (FDA) regulations commonly known as the Animal Rule.

• September 18, 2019
  

  C-Path’s Martha A. Brumfield Named Arizona Bioscience Leader of the Year

      CHANDLER, Ariz., Sept. 18, 2019 — The Arizona Bioindustry Association (AZBio) today announced that Martha A. Brumfield, PhD, Special Advisor to the CEO and past President and CEO at the Critical Path Institute (C-Path) will be honored as the Jon W. McGarity Arizona Bioscience Leader of the Year at the 2019 AZBio Awards......